Cancer and neoplasms
Trabedersen by Oncotelic Therapeutics for Metastatic Melanoma: Likelihood of Approval
Nov
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Trabedersen overview
Trabedersen (OT-101) is under development for the treatment of pancreatic carcinoma, glioblastoma, myelodysplastic syndrome (MDS), long covid-19, malignant melanoma, high grade glioma, colorectal carcinoma and solid tumor in combination with immunotherapy (NK/IL-2) and pediatric diffuse intrinsic pontine glioma. The drug candidate is administered by intravenous, infusion and intratumoral route as a solution. It is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer). It is also under development for pneumonia and coronavirus disease 2019 (COVID-19). It was also under development for lung cancer, renal cell cancer, prostate cancer, refractory anaplastic astrocytoma (AA) and other neoplasms.
It was also under development for malignant pleural mesothelioma and non-small cell lung cancer.
Oncotelic Therapeutics overview
Oncotelic Therapeutics, Inc. (OTI) is a pharmaceutical and healthcare company developing investigational drugs for the treatment of orphan oncology indications. The company develops therapeutics to treat cancer and eye diseases; and anti-vascular drugs such as vascular disrupting agents. OTI is developing a product for treatment of anaplastic thyroid cancer, medullary thyroid cancer, stage IV papillary thyroid cancer, ovarian cancer, stage IV follicular thyroid cancer, and others. OTI offers development pipeline such as CA4P and Oxi4503. The company also conducts multiple clinical trials in oncology to discover small-molecule anticancer agents belong to benzosuberene class of compound. It operates through researchers in the University of Florida and the University of Arhus on anti-angiogenic and anti-metastatic agents. Oxigene is headquartered in South San Francisco, California, the US.
For a complete picture of Trabedersen’s drug-specific PTSR and LoA scores, buy the report here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
